NCT03159442View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

June 19, 2017

Primary Completion Date

October 13, 2017

Study Completion Date

October 13, 2017

Conditions

Chronic Obstructive Pulmonary Disease - COPD

Interventions

DRUG

AZD8871

Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.

DRUG

Placebo

Powder for inhalation administered via single dose DPI

Trial Locations (1)

HA1 3UJ

Research Site, London

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

collaborator

Industrias Farmacéuticas Almirall S.A.

UNKNOWN

collaborator

The Doctors Laboratory Ltd

INDUSTRY

collaborator

Covance

INDUSTRY

lead

AstraZeneca

INDUSTRY